These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

160 related articles for article (PubMed ID: 33350691)

  • 21. USA stockpiling of remdesivir: How should the world respond?
    Dawoud D; Chalkidou K; Sullivan R; Ruiz FJ; Adler A
    J Comp Eff Res; 2020 Dec; 9(18):1243-1246. PubMed ID: 33274643
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Arguments in favour of remdesivir for treating SARS-CoV-2 infections.
    Ko WC; Rolain JM; Lee NY; Chen PL; Huang CT; Lee PI; Hsueh PR
    Int J Antimicrob Agents; 2020 Apr; 55(4):105933. PubMed ID: 32147516
    [No Abstract]   [Full Text] [Related]  

  • 23. Remdesivir for the treatment of COVID-19 in pregnancy.
    Lampejo T
    J Med Virol; 2021 Jul; 93(7):4114-4119. PubMed ID: 33788273
    [No Abstract]   [Full Text] [Related]  

  • 24. What Do We Know About Remdesivir Drug Interactions?
    Yang K
    Clin Transl Sci; 2020 Sep; 13(5):842-844. PubMed ID: 32402130
    [No Abstract]   [Full Text] [Related]  

  • 25. Remdesivir for COVID-19 in Europe: will it provide value for money?
    Dal-Ré R; Banzi R; Georgin-Lavialle S; Porcher R; Sofat R; Zeitlinger M; Rosendaal FR
    Lancet Respir Med; 2021 Feb; 9(2):127-128. PubMed ID: 33341157
    [No Abstract]   [Full Text] [Related]  

  • 26. Update Alert 2: Should Remdesivir Be Used for the Treatment of Patients With COVID-19? Rapid, Living Practice Points From the American College of Physicians (Version 2).
    Qaseem A; Yost J; Etxeandia-Ikobaltzeta I; Abraham GM; Jokela JA; Miller MC; Forciea MA; Humphrey LL;
    Ann Intern Med; 2021 Dec; 174(12):W116-W117. PubMed ID: 34606308
    [No Abstract]   [Full Text] [Related]  

  • 27. Safety profile of the antiviral drug remdesivir: An update.
    Fan Q; Zhang B; Ma J; Zhang S
    Biomed Pharmacother; 2020 Oct; 130():110532. PubMed ID: 32707440
    [No Abstract]   [Full Text] [Related]  

  • 28. Remdesivir (GS-5734) in COVID-19 Therapy: The Fourth Chance.
    Moirangthem DS; Surbala L
    Curr Drug Targets; 2021; 22(12):1346-1356. PubMed ID: 33267759
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Should Remdesivir Be Used for the Treatment of Patients With COVID-19? Rapid, Living Practice Points From the American College of Physicians (Version 2).
    Qaseem A; Yost J; Etxeandia-Ikobaltzeta I; Abraham GM; Jokela JA; Forciea MA; Miller MC; Humphrey LL; ; Centor RM; Andrews R; Haeme R
    Ann Intern Med; 2021 May; 174(5):673-679. PubMed ID: 33560862
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Remdesivir as a broad-spectrum antiviral drug against COVID-19.
    Hong YN; Xu J; Sasa GBK; Zhou KX; Ding XF
    Eur Rev Med Pharmacol Sci; 2021 Jan; 25(1):541-548. PubMed ID: 33506946
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Remdesivir for the Treatment of COVID-19.
    Allen R; Turner M; deSouza IS
    Am Fam Physician; 2022 Feb; 105(2):131-132. PubMed ID: 35166509
    [No Abstract]   [Full Text] [Related]  

  • 32. Remdesivir for the treatment of COVID 19: review of the pharmacological properties, safety and clinical effectiveness.
    Mechineni A; Kassab H; Manickam R
    Expert Opin Drug Saf; 2021 Nov; 20(11):1299-1307. PubMed ID: 34338121
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Timing of remdesivir for COVID-19.
    Med Lett Drugs Ther; 2020 Oct; 62(1609):161. PubMed ID: 33429407
    [No Abstract]   [Full Text] [Related]  

  • 34. Remdesivir potently inhibits carboxylesterase-2 through covalent modifications: signifying strong drug-drug interactions.
    Shen Y; Eades W; Yan B
    Fundam Clin Pharmacol; 2021 Apr; 35(2):432-434. PubMed ID: 33369768
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Major Update 2: Remdesivir for Adults With COVID-19.
    Finsterer J
    Ann Intern Med; 2022 Aug; 175(8):W81. PubMed ID: 35969872
    [No Abstract]   [Full Text] [Related]  

  • 36. Major Update 2: Remdesivir for Adults With COVID-19.
    Kaka AS; Wilt TJ
    Ann Intern Med; 2022 Aug; 175(8):W81-W82. PubMed ID: 35969873
    [No Abstract]   [Full Text] [Related]  

  • 37. Plasma concentrations of remdesivir metabolite in a critical COVID-19 patient needing continuous venovenous haemodialysis.
    Tempestilli M; Stazi GV; Maffongelli G; Marini MC; Ascoli Bartoli T; Ippolito G; Nicastri E; Marchioni L; Agrati C
    Eur J Clin Pharmacol; 2021 Oct; 77(10):1583-1585. PubMed ID: 33982133
    [No Abstract]   [Full Text] [Related]  

  • 38. Clinical course and serial chest ultra-low-dose CT findings in a patient with COVID-19 treated with remdesivir.
    Grazioli-Gauthier L; Vanini G; Argentieri G; Bernasconi E; Gianella P
    Minerva Med; 2021 Aug; 112(4):516-518. PubMed ID: 34269015
    [No Abstract]   [Full Text] [Related]  

  • 39. Regulatory approval for COVID-19 across the globe.
    Mahalmani V; Pugazhenthan T; Mittal N; Varthya SB; Medhi B
    Indian J Pharmacol; 2020; 52(6):457-466. PubMed ID: 33666185
    [No Abstract]   [Full Text] [Related]  

  • 40. Clinical pharmacodynamics of obeldesivir versus remdesivir.
    Faghihi I; Yan VC
    Antimicrob Agents Chemother; 2024 Sep; 68(9):e0096924. PubMed ID: 39133123
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.